Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendis Pharma (ASND) Gets a Buy Rating from Canaccord Genuity
10:09am, Tuesday, 31'st Mar 2020
In a report released today, Michelle Gilson from Canaccord Genuity maintained a Buy rating on Ascendis Pharma (ASND – Research
Ascendis Pharma A/S (ASND) Scheduled to Post Earnings on Wednesday
05:54am, Tuesday, 31'st Mar 2020
Ascendis Pharma A/S (NASDAQ:ASND) is scheduled to release its earnings data after the market closes on Wednesday, April 1st. Analysts expect Ascendis Pharma A/S to post earnings of ($1.27) per share f
Ascendis Pharma A/S (NASDAQ:ASND) Receives "Buy" Rating from Bank of America
06:00am, Monday, 30'th Mar 2020
Bank of America reissued their buy rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report report published on Friday morning, AnalystRatings.com reports. They currently have a $145
Comparing Ascendis Pharma A/S (NASDAQ:ASND) and Zosano Pharma (NASDAQ:ZSAN)
09:44am, Sunday, 29'th Mar 2020
Ascendis Pharma A/S (NASDAQ:ASND) and Zosano Pharma (NASDAQ:ZSAN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valua
Alliancebernstein L.P. Buys 1,940 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
08:46am, Sunday, 29'th Mar 2020
Alliancebernstein L.P. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutiona
Bank of America Reiterates "Buy" Rating for Ascendis Pharma A/S (NASDAQ:ASND)
06:06am, Sunday, 29'th Mar 2020
Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “buy” rating reaffirmed by stock analysts at Bank of America in a report issued on Friday, AnalystRatings.com reports. They currently have a $14
Ascendis Pharma (ASND) Gets a Buy Rating from Merrill Lynch
10:44pm, Saturday, 28'th Mar 2020
Merrill Lynch analyst
Tazeen Ahmad
maintained a
Buy
rating on Ascendis Pharma (
ASND
–
Research Report
) on March 23 and set a price target of
$145.00
. The company’s shares closed last Monday at
Ascendis Pharma A/S (NASDAQ:ASND) Lifted to "Buy" at Zacks Investment Research
09:08am, Saturday, 28'th Mar 2020
Zacks Investment Research upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research note released on Tuesday morning, Zacks.com reports. Zacks Investment Re
BlackBerry (BB) to Report Q4 Earnings: What's in the Offing?
11:05am, Friday, 27'th Mar 2020
BlackBerry's (BB) fiscal fourth-quarter performance is likely to have benefited from its investment in product development and go-to-market strategy.
BlackBerry (BB) to Report Q4 Earnings: What's in the Offing?
11:05am, Friday, 27'th Mar 2020
BlackBerry's (BB) fiscal fourth-quarter performance is likely to have benefited from its investment in product development and go-to-market strategy.
Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1
08:01pm, Wednesday, 25'th Mar 2020
COPENHAGEN, Denmark, March 25, 2020 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet.
What's in Store for Science Applications' (SAIC) Q4 Earnings?
11:33am, Wednesday, 25'th Mar 2020
Science Applications' (SAIC) fourth-quarter fiscal 2020 results are likely to reflect gains from new business wins and the Engility acquisition.
What's in Store for Science Applications' (SAIC) Q4 Earnings?
11:33am, Wednesday, 25'th Mar 2020
Science Applications' (SAIC) fourth-quarter fiscal 2020 results are likely to reflect gains from new business wins and the Engility acquisition.
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by BidaskClub to "Buy"
07:40am, Wednesday, 25'th Mar 2020
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday, BidAskClub reports. ASND has been the subject of a number o
Barclays PLC Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)
08:36am, Tuesday, 24'th Mar 2020
Barclays PLC cut its position in Ascendis Pharma A/S (NASDAQ:ASND) by 95.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 378 share
